ClinicalTrials.gg
RecruitingNCT05982093SOLTI-2104Updated Apr 24, 2026

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

A Phase 2 interventional study of Elacestrant and Triptorelin in Breast Cancer, HER2-negative Breast Cancer and Hormone Receptor Positive Tumor, sponsored by SOLTI Breast Cancer Research Group. Recruiting at 15 sites in Spain. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by SOLTI Breast Cancer Research Group · Phase 2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Feb 2023, registered Jul 2023).
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
35 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies testing elacestrant in Breast Neoplasms — 15 open to participants now, 18 under way, 3 of them phase 3. elacestrant · Breast Neoplasms.

Planned enrollment
11th of 24
96 · median 72
Started
2023
with 5 others
Phase 2
11 of 24
10 open now
Primary completion
2026-12
later than 1 of 17 live
Registered
10th of 24
by date
Lead sponsor
2 of 24
SOLTI Breast Cancer Research Group

Among the 24 studies testing elacestrant in Breast Neoplasms, this one is the 11th largest by planned enrollment, is one of 6 that started in 2023, is one of 11 in phase 2, reaches primary completion later than 1 of the 17 other live ones, and was the 10th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 24 studies testing elacestrant in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About elacestrant

elacestrant: first FDA approval 2023 (ORSERDU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 35 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing elacestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

PREMIERE parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study in premenopausal women with primary operable HR+/HER2-negative breast cancer with aiming at evaluating the biological effects of elacestrant with or without triptorelin.

Read the detailed description

PremiÈRe Part A and Part B are parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory trials designed to evaluate the biological activity of elacestrant in premenopausal women with primary operable HR+/HER2- BC.

Eligible patients must have histologically confirmed, operable, HR+/HER2-invasive breast cancer >1 cm, with a Ki67 between 10-35%, be treatment-naïve, and meet all other inclusion and exclusion criteria. An FFPE tumor sample of sufficient quality must be available, if not, patients must agree to undergo a re-biopsy.

In Part A, patients are randomized 1:1 to receive one of the following regimens:

  • Elacestrant arm: 400 mg orally once daily for 30 (+7) days.
  • Elacestrant + triptorelin arm: same elacestrant schedule plus triptorelin 3.75 mg on days 1 and 29.

In Part B, patients are randomized 1:1 to receive one of the following regimens:

  • Elacestrant arm: 400 mg orally once daily for 30 (+7) days
  • Tamoxifen arm: 20 mg orally once daily for 30 (+7) days.

Randomization is stratified by PAM50 intrinsic subtype (Luminal A vs non-Luminal A), determined by research-based molecular profiling.

During the treatment period, blood samples will be collected for the isolation of plasma and serum at baseline, Day 14, Day 28, and post-treatment. In PremiÈRe Part B only, optional transvaginal ultrasound (TVUS) assessments may be performed at baseline, Day 28, and at the End of Study visit, to explore changes in ovarian and uterine parameters.

Following treatment, breast and axillary surgery will be performed according to local practice procedures. Pre-surgical sentinel lymph node biopsy (SLNB) is not allowed. Surgical specimens (or mandatory biopsy samples if no surgery is planned) will be collected for analysis.

A post-surgery visit will occur within 28 ± 14 days and will mark the end of active follow-up.

03

Conditions studied

  • Breast Cancer
  • HER2-negative Breast Cancer
  • Hormone Receptor Positive Tumor
  • Premenopausal Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed must be obtained prior to any trial-specific procedure.
  2. Female patients who are at least 35 years of age on the day of signing informed consent.
  3. Patient is premenopausal at the time of study entry

    Premenopausal status is defined as either:

    • Patient had last menstrual period within the last 6 months. OR
    • Plasma estradiol and FSH in the premenopausal range, according to local laboratory definition.

    Note: Patients who have undergone bilateral oophorectomy are not eligible.

  4. confirmed non- primary invasive adenocarcinoma of the breast untreated and recently diagnosed, with all the following characteristics:

    • Stage I to stage IIB operable breast cancer (7th Edition of the AJCC). Note: Axillary lymph node status must be assessed by fine needle or core biopsy. This procedure at screening will be omitted if there is no suspicion for positive axillary lymph node(s) radiographically or if a pathological report of suspicious lymph nodes of the results of a fine needle biopsy or core biopsy is available prior to the screening period.
    • Absence of distant metastasis (i.e., M0) as determined by institutional practice.
    • At least 1 lesion that can be accurately and serially measured in at least 1 dimension and for which the longest diameter is ≥ 10 mm as measured by magnetic resonance imaging (MRI) or ultrasound (US).
    • In the case of a multifocal tumor, the largest lesion must be ≥ 10 mm and designated the "target" lesion for all subsequent tumor evaluations. All biopsied tumors had to be ER+-negative
  5. ER-positive with expression higher than 10% and HER2-negative tumor

    • HER2 negativity is defined as either of the following: Immunohistochemistry (IHC) 0, IHC 1+ or IHC2+/in situ hybridization (ISH) negative as per most recent American Society of Clinical Oncology (ASCO)-College of American Pathologists Guideline (CAP) guideline according to the local laboratory as determined on the most recently analyzed tissue sample.
    • Documentation of ER positive tumor with ≥ 10% staining by immunohistochemistry of cells as per most recent ASCO-CAP guideline according to the local laboratory determined on the most recently analyzed tissue sample, with or without progesterone receptor positivity.
  6. Ki67 expression ≥ 10% and ≤ 35% by local assessment
  7. Have an (ECOG) performance status of 0 to 1.
  8. Breast cancer eligible for primary surgery.
  9. Availability of pre-treatment tumor tissue sample of FFPE tumor block from primary tumor for biomarker analysis. The tumor tissue should be of good quality based on total and viable tumor content and must be evaluated centrally for quality prior to enrollment. Archival tumor tissue or ex professo biopsy are acceptable.
  10. Adequate hematologic and organ function within 14 days before the first study treatment on Day 1, defined by the following:

    1. Neutrophils ( ≥1.000/μL).
    2. ≥ 9.0 g/dL (with no need for transfusions).
    3. count ≥ 75. 000/μL.
    4. Serum creatinine ≤1.5 mg/dL or calculated ≥30 mL/min (Cockcroft-Gault Equation)
    5. (INR) or prothrombin time (PT) ≤1.5 × and activated partial thromboplastin time (aPTT) within therapeutic range.

      Note: Subjects who are receiving anticoagulation treatment which is monitored by INR (eg, warfarin) may be allowed to participate if they have a stable INR (ie, within therapeutic range) for at least 28 days prior to the first dose of study drug, in the absence of any exclusionary medical conditions, and provided that elacestrant would be appropriate therapy for the subject

    6. Potassium, total Calcium (corrected for serum albumin), and sodium v5.0 Grade ≤ 1.
    7. (ALT) ≤ 3x upper limit of normal (ULN)
    8. Aspartate aminotransferase (AST) ≤ 3x ULN
    9. Total ≤ ULN or total bilirubin ≤ 1.5x ULN with direct bilirubin ≤ ULN of the laboratory in subjects with documented Gilbert's Syndrome
  11. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.
  12. Women of (CBP), defined as all women physiologically capable of becoming pregnant, must have confirmed negative serum pregnancy test within 7 days prior to randomization.
  13. Female subjects must not donate, or retrieve for their own use, oocytes from the time of screening and throughout the study treatment period, and for at least 120 days after the time of final study drug administration.
  14. Women of CBP must be willing to use highly effective methods of . Contraception must continue during the trial treatment and after stopping the treatment received according to protocol. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    • Placement of a non-hormonal intrauterine device (IUD). Notes: Use of oral (estrogen and progesterone), transdermal, injected, implanted, hormone containing intrauterine system, or any other hormonal methods of contraception is not allowed in this trial. Women are considered of CBP unless: they have had ≥ 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e., age-appropriate history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least four weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment, she will be considered not of CBP. After the end of trial treatment, patients should use effective contraception at least until 28 days after therapy discontinuation.
  15. Patients must have the ability to swallow oral medication.

Exclusion criteria

Exclusion Criteria:

  1. Inoperable locally advanced or inflammatory breast cancer (any stage III).
  2. (Stage IV) breast cancer.
  3. Synchronous invasive bilateral or multicentric breast cancer.
  4. Patients requiring immediate chemotherapy or immediate surgical intervention.
  5. Patients who have undergone sentinel lymph node or tumor excisional biopsy prior to study treatment.
  6. Prior within 3 years prior to randomization, except curatively treated non-melanoma skin cancer, in situ cancer or adequately and curatively treated Stage I or II cancer from which the patient is currently in complete remission.
  7. Patients currently on following medications, which cannot be interrupted 7 days prior treatment start:

    • Any prohibited medication as per decapeptyl (triptorelin) label
    • Strong inhibitors of , including grapefruit, grapefruit hybrids, pummelos, starfruit and Seville oranges
    • Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 (Refer to http://medicine.iupui.edu/clinpharm/ddis/) within 5 half-life of the drug prior to initiating trial therapy
    • Herbal preparations/medications. These include, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng within 5 half-life of the drug prior to initiating trial therapy
    • Vaccination, including but not limited to vaccination against COVID-19, during the 7 days prior to randomization.
  8. Any treatment, local or systemic, including prior chemotherapy, ET, targeted therapy, and/or radiation therapy for the currently diagnosed BC prior to enrollment.
  9. Major surgical procedure or significant traumatic injury within 28 days prior to randomization.
  10. Assessment by the investigator to be unable or unwilling to comply with the requirements of the protocol.
  11. Any of the following within 6 months before enrollment: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of v5.0 Grade ≥ 2, prolonged ≥ Grade 2 (i.e., > 480 msec), uncontrolled atrial fibrillation of any grade, coronary/peripheral artery bypass graft, heart failure ≥ Class II as defined by the guidelines, or cerebrovascular accident including .
  12. Score greater than Class A (i.e., score >6)
  13. Coagulopathy or any history of coagulopathy within the past 6 months, including history of deep vein thrombosis or pulmonary embolism. However, subjects with the following conditions will be allowed to participate:

    1. Adequately treated catheter-related venous thrombosis occurring >28 days prior to the first dose of study drug
    2. Treatment with an anticoagulant, e.g., warfarin or heparin, for a thrombotic event occurring > 6 months before enrollment, or for an otherwise stable and allowed medical condition (eg, well controlled atrial fibrillation), provided dose and coagulation parameters (as defined by local standard of care) are in therapeutic range prior to the first dose of study drug and provided that an AI would be an appropriate therapy for the subject
  14. Known to any of the study drugs, including .
  15. Known difficulty in tolerating oral medications or conditions which would impair absorption of oral medications such as: uncontrolled nausea or vomiting (i.e., CTCAE ≥ Grade 3 despite antiemetic therapy), ongoing gastrointestinal obstruction/motility disorder, malabsorption syndrome, or prior gastric bypass.
  16. History of or clinical evidence of significant co-morbidities that, in the judgment of the investigator, may interfere with the conduction of the study, the evaluation of response, or with .
  17. Previous hormonal treatments for other indications such as osteoporosis, breast cancer prevention, hormonal substitutive therapy, such as raloxifene, tamoxifen, estrogen, progestins must have ended at least 12 months prior to trial registration. If a patient is on natural products known to contain progestins, they must be stopped 14 days prior to beginning study treatment.
  18. Used any prescription medication during the prior 1 month that the investigator judge is likely to interfere with the study or to pose an additional risk to the patient in participating.
  19. Female subject who is pregnant or breastfeeding or intends to become pregnant during the study.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Elacestrant

    without ovarian function suppression

    Drug: Elacestrant

  • Active comparator
    Elacestrant + Triptorelin

    with ovarian function suppression

    Drug: Elacestrant · Drug: Triptorelin

  • Active comparator
    Tamoxifen

    monotherapy

    Drug: Tamoxifen 20 mg

Interventions

  • Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).

    Also known as: Orserdu

  • Monthly triptorelin 3.75 mg powder and solvent for prolonged-release suspension for injection. Each vial contains 3.75 mg of triptorelin (acetate). After reconstitution with 2 ml of solvent, 1 ml of the suspension contains 1.875 mg triptorelin. This drug contains sodium, but less than 1 mmol (23 mg) of sodium per vial.Triptorelin will be administrated on D1 and D29.

    Also known as: Orserdu

  • DrugTamoxifenStudies of TamoxifenTamoxifen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tamoxifen 20 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).

06

What researchers measure

Primary outcomes

  1. To evaluate the biological activity of elacestrant with or without OFS in premenopausal women with ER+/HER2- operable EBC

    Rate of CCCA determined by central assessment by IHC Ki67 (% Ki67 ≤ 2.7%) after 4 weeks of therapy.

    Time frame: After 30 days (+7 days) of therapy

Secondary outcomes

  1. To evaluate the biological activity of elacestrant with or without OFS in premenopausal women with ER+/HER2- operable EBC according to baseline research-based PAM50 subtype.

    Rate of CCCA determined by central assessment by IHC Ki67 (% Ki67 ≤ 2.7%) after short-term elacestrant therapy with or without OFS for patients Luminal A and Non-Luminal A.

    Time frame: After 30 days (+7 days) of therapy

  2. To evaluate the antiproliferative activity of elacestrant with or without OFS after -treatment

    Mean change in Ki67 measured by IHC Ki67 expression between pre- and post-treatment samples. - Differences in differential expression of proliferative genes

    Time frame: After 30 days (+7 days) of therapy

  3. To identify changes in the research-based PAM50 subtypes pre- and post-treatment samples after treatment

    Proportion of patients switching subtype between pre- and post-treatment samples

    Time frame: After 30 days (+7 days) of therapy

  4. To evaluate the effect of optimal and suboptimal OFS (E2 level greater than 2.72 pg/mL) in CCCA

    Mean change in measured by Ki67 expression between pre- and post-treatment samples and CCCA rate determined by Ki67 ≤ 2.7% between pre- and post-treatment samples of elacestrant therapy with or without OFS

    Time frame: After 30 days (+7 days) of therapy

  5. To evaluate levels of E2 in blood.

    Mean change of E2 levels between pre- and during treatment (D14) and pre-surgery samples

    Time frame: After 14 days (+2 days) of therapy

  6. To evaluate levels of FSH in blood.

    Mean change of FSH levels between pre- and during treatment (D14) and pre-surgery samples

    Time frame: After 14 days (+2 days) of elacestrant therapy

  7. To evaluate the safety of the treatments when administered in pre-menopausal patient population.

    Incidence and severity of adverse events, with severity, determined according to NCI CTAE v.5.0.

    Time frame: Until End of Study Visit (7-28 days after surgery)]

  8. To evaluate the tolerability of the treatments when administered in pre-menopausal patient population.

    Change from baseline in targeted clinical laboratory test results, including ECGs

    Time frame: Until End of Study Visit (7-28 days after surgery)]

07

Study locations

15 of 15 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 46 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2023
First posted
Aug 8, 2023
StartActual
Feb 3, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05982093
Lead sponsor
SOLTI Breast Cancer Research Group
Responsible party
Sponsor
First posted
Aug 8, 2023
Start date
Feb 3, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 24, 2026

Study contacts

Sara Cano, PhD
Contact
info@gruposolti.org
+ 34 933 436 302
Juan M Ferrero, PharmD
Contact
info@gruposolti.org
+ 34 933 436 302

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elacestrant

Start the discussion